absolutely and the first part of the trial just passed was short and mixed dose. The one being recruited for will be representative and potentially show enhanced data points with the best dose and duration. I also read somewhere might have been on one of these threads that they feel it’s one of more potent fak inhibitors in vitro so far based on comparative data but I might be wrong. Dyor
ATX Price at posting:
7.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)